<DOC>
	<DOCNO>NCT02499614</DOCNO>
	<brief_summary>Phase II , two arm , parallel , non comparative study crizotinib patient ROS 1 translocation MET amplification</brief_summary>
	<brief_title>Crizotinib Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification ROS1 Translocation ( METROS )</brief_title>
	<detailed_description>This phase II , prospective , two arm , parallel , non comparative study crizotinib pretreated NSCLC patient ROS1 translocation MET amplification . Patients locally advance metastatic NSCLC , pretreated least one previous chemotherapy line least one measurable tumor lesion consider eligible trial . All potentially eligible patient evaluate MET ROS1 FISH detect MET amplification ROS1 translocation After evaluation inclusion exclusion criterion , signature inform consent form , MET amplify ROS1 translocate eligible patient receive crizotinib 250 mg BID p.o disease progression , unacceptable toxicity patient refusal .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Histologically confirm diagnosis NSCLC Availability tumor tissue ROS1 MET analyse Patient positive ROS1 translocation MET amplification At least one radiological measurable disease accord RECIST criterion ( Response Evaluation Criteria Solid Tumors ) At least 1 previous standard chemotherapy regimen Performance status 02 ( ECOG ) Patient compliance trial procedure age ≥ 18 year Written inform consent Adequate BM function ( ANC ≥ 1.5x109/L , Platelets ≥ 100x109/L , HgB &gt; 9g/dl ) Adequate liver function ( bilirubin &lt; G2 , transaminases 3xULN/ &lt; 5xULN present liver metastasis ) . Normal level alkaline phosphatase creatinine . If female : childbearing potential either terminate surgery , radiation , menopause , attenuate use approve contraceptive method [ intrauterine contraceptive device ( IUD ) , birth control pill , barrier device ] ninety ( 90 ) day end treatment . No tumor tissue available patient negative ROS1 translocation MET amplification Absence measurable lesion For ROS1+ patient : Previous therapy crizotinib antiALK agent For MET amplify patient : Evidence MET amplification tumor tissue collect EGFR mutant patient time EGFRTKI acquire resistance occurrence . An EGFR mutant patient eligible MET amplification detect tumor specimen collect start EGFRTKI No previous chemotherapy Concomitant radiotherapy chemotherapy . Previous radiotherapy target lesion ( ) . If site include radiotherapy field patient eligible evidence progressive disease completion radiotherapy . Symptomatic brain metastasis Diagnosis malignancy last 5 year , except situ carcinoma cervix uteri squamous cell carcinoma skin Pregnancy lactate Other serious illness medical condition potentially interfere study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>MET amplification</keyword>
	<keyword>ROS1 translocation</keyword>
	<keyword>Crizotinib</keyword>
</DOC>